The European Federation of Immunological Societies is awarding Klaus Rajewsky of the Max Delbrück Center its first-ever Lifetime Achievement Award. The 88-year-old Rajewsky, who remains active in research, is being recognized for his pioneering work…

If the brain no longer responds properly to insulin (insulin resistance), this can lead to overweight, diabetes, and Alzheimer's disease. Researchers at the German Center for Diabetes Research (DZD) in Potsdam and Tübingen have discovered small…

Collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancreatic, colorectal and lung cancer / KRAS mutations occur in nearly 25 percent of human cancers, with the…

Guest professor at the Cognitive Computational Neuroscience Lab, Freie Universität Berlin, uses language models similar to those behind ChatGPT

Neuroblastoma, a cancer mainly affecting children, is often difficult to treat. Researchers at Charité – Universitätsmedizin Berlin and the Max Delbrück Center now report a potential reason treatment sometimes fails. In the journal Cancer Discovery,*…

An interdisciplinary team of scientists from the Berlin Institute of Health at Charité (BIH), the Max Delbrück Center, the German Cancer Research Center (DKFZ), the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) and…

Beyond the hype: We are looking for AI and quantum technologies with real added value

Apply by 17 August 2025!

The EU-Japan Centre is targeting cutting-edge technologies sectors for its very first Innovation mission to Japan.

Deadline: 24.08.2025

Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contract manufacturing of its novel investigational…